Galmed Pharmaceuticals Ltd. (GLMD)
Galmed Pharmaceuticals Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ramat Gan, TA, IL. The stock last traded at $0.56, up 0.27% on the session, giving a market capitalisation of $4.6M. On trailing twelve-month figures it carries a trailing P/E of -0.28, a net margin of 0.0%. Its beta of 0.74 implies it has historically moved less than the broad market.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Galmed Pharmaceuticals Ltd. is most often compared with the following Healthcare names: